BHVN Stock Recent News
BHVN LATEST HEADLINES
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN).
Volatile biotech stock Biohaven (BHVN -19.41%) is prone to sharp movements both up and down. On Thursday, it had one of its down days, with its share price eroding by almost 20% on a development with a top regulator.
NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN).
Biohaven Ltd. BHVN shares plunged on Thursday after the Food and Drug Administration (FDA) unexpectedly delayed the review date for its rare-disease drug troriluzole.
- Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. - Troriluzole has been granted Fast-Track, Orphan Drug Designation (ODD) and Priority Review from the FDA.
BHVN's lead asset is Troriluzole, which is nearing a pivotal FDA decision by August 2025. The company also recently secured an additional $600 million financing through secured notes with Oberland Capital. Moreover, BHVN's pipeline is diverse, including other neurology, immunology, oncology, and obesity programs.
Shares of Biohaven (BHVN 5.24%) are surging on Monday. The company's stock was up about 8% as of midday trading and had climbed as much as 10% earlier in the day.
Up to $600 million in non-dilutive capital in exchange for capped milestone and royalty payments on future troriluzole product net sales $250 million to be funded at closing $150 million available at the Company's option upon the achievement of regulatory milestones related to troriluzole Up to $200 million at the mutual agreement of the parties for permitted strategic acquisitions and related costs and expenses NEW HAVEN, Conn. , April 28, 2025 /PRNewswire/ -- Biohaven Ltd.
On Friday's news that Biohaven (BHVN -15.34%) withdrew its application for a top investigational drug from an important regulator, investors aggressively traded out of the stock. The clinical-stage biotech was one of the biggest decliners in its industry, exiting Friday with a share price decline of over 15%.
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.